{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:31:48Z","timestamp":1790818308351,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002913.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000}}],"reference-count":53,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002913.pub3","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T23:32:20Z","timestamp":1408577540000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Budesonide for maintenance of remission in Crohn's disease"],"prefix":"10.1002","volume":"2020","author":[{"given":"M Ellen","family":"Kuenzig","sequence":"first","affiliation":[{"name":"The Children's Hospital of Eastern Ontario; Division of Gastroenterology Hepatology & Nutrition; 401 Smyth Road Ottawa ON Canada K1H 8L1"},{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rezaie","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center; Department of Medicine; Los Angeles California USA 90048"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"},{"name":"University of Calgary; Department of Medicine; TRW Building Rm 6D18 3280 Hospital Drive NW Calgary AB Canada T2N 4Z6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R","family":"Otley","sequence":"additional","affiliation":[{"name":"IWK Health Centre; Head, Division of Gastroenterology; 5850 University Avenue Halifax NS Canada B3K 6R8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital; Department of Medicine, Division of Gastroenterology; Room 445, 600 University Avenue Toronto ON Canada M5G 1X5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Ave. Toronto ON Canada M5G 1X8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"},{"name":"University of Calgary; Department of Medicine; TRW Building Rm 6D18 3280 Hospital Drive NW Calgary AB Canada T2N 4Z6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Eastern Ontario; Division of Gastroenterology Hepatology & Nutrition; 401 Smyth Road Ottawa ON Canada K1H 8L1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,21]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD002913.pub3-BIB0002|cit2","first-page":"339","article-title":"Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission","volume":"65","author":"Jong","year":"2007","journal-title":"Netherlands Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","article-title":"Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group","volume":"11","author":"Ewe","year":"1999","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group","volume":"12","author":"Ferguson","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002913.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD002913.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0013|cit13","article-title":"Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomized trial","author":"Dignass","journal-title":"Journal of Crohn's and Colitis"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/00365520310000645a","article-title":"Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease","volume":"38","author":"Ecker","year":"2003","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD002913.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2036.2001.01055.x","article-title":"Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules","volume":"15","author":"Green","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD002913.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ibd.20881","article-title":"Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial","volume":"15","author":"Levine","year":"Jul 2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0017|cit17","first-page":"235","article-title":"Oral budesonide - A further step in the prevention of relapse in Crohn's disease? [German]","volume":"27","author":"Pohl","year":"1997","journal-title":"Leber, Magen, Darm"},{"issue":"8","key":"10.1002\/14651858.CD002913.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials","volume":"100","author":"Sandborn","year":"2005","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0021|cit21","unstructured":"Safety and maintenance study of entocort for children with Crohn's disease Ongoing study December 2011"},{"issue":"12","key":"10.1002\/14651858.CD002913.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0165-6147(93)90184-L","article-title":"Anti-inflammatory actions of steroids: molecular mechanisms","volume":"14","author":"Barnes","year":"1993","journal-title":"Trends in Pharmacological Sciences"},{"issue":"9573","key":"10.1002\/14651858.CD002913.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD002913.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MPG.0b013e31805563f3","article-title":"Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America","volume":"44","author":"Bousvaros","year":"2007","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0016-5085(98)70476-7","article-title":"Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum","volume":"114","author":"D'Haens","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0029|cit29","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch5","article-title":"Assessing the quality of randomised controlled trials","volume-title":"Systematic reviews in health care: meta-analysis in context","author":"Juni","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"7650","key":"10.1002\/14651858.CD002913.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"8167","key":"10.1002\/14651858.CD002913.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"7414","key":"10.1002\/14651858.CD002913.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0034|cit34","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn's disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD002913.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008480-200010000-00005","article-title":"Corticosteroids in the treatment of gastrointestinal disease","volume":"12","author":"Hyams","year":"2000","journal-title":"Current Opinion in Pediatrics"},{"issue":"9","key":"10.1002\/14651858.CD002913.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1542\/pir.26.9.314","article-title":"Inflammatory bowel disease","volume":"26","author":"Hyams","year":"2005","journal-title":"Pediatrics in Review"},{"issue":"6","key":"10.1002\/14651858.CD002913.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1428-35; quiz 1","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD002913.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of severity of Crohn's disease: a prospective multicentre study. Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2013.240","article-title":"IBD across the age spectrum-is it the same disease?","volume":"11","author":"Ruel","year":"2014","journal-title":"Nature Reviews. Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002913.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/01.MIB.0000184849.38816.39","article-title":"Design issues and outcomes in IBD clinical trials","volume":"11","author":"Sands","year":"2005","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0044|cit44","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD002913.pub3-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000296.pub3","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Seow","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4 Supp 1","key":"10.1002\/14651858.CD002913.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/S0016-5085(03)80128-2","article-title":"Budesonide versus prednisolone in the management of Crohn's disease: a randomized multi-national 2-year study","volume":"124","author":"Stockbrugger","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.gastro.2006.12.037","article-title":"A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis","volume":"132","author":"Su","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD002913.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2005.02846.x","article-title":"High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance","volume":"141","author":"Towers","year":"2005","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD002913.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2002.tb04628.x","article-title":"Treating Crohn's disease by inducing T lymphocyte apoptosis","volume":"973","author":"Brande","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.21.4.279","article-title":"An index of inflammatory activity in patients with Crohn's disease","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD002913.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD002913.pub3-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002913.pub2","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Benchimol","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002913.pub3-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Simms","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002913.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:22:48Z","timestamp":1665055368000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002913.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,21]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002913.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,21]]}}}